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Natural killer (NK) cells are an important component of the immune response to influenza 
infection, but are subject to alteration during aging, which may play a role in impaired 
response to infection and vaccination in older people. Enhancement of NK cell activity 
could, therefore, present a means to improve the immune response to vaccination 
in older subjects, and pre- and probiotics offer an opportunity to modulate antiviral 
defenses via alteration of the gut microbiota. This study investigated the effect of a novel 
probiotic, Bifidobacterium longum bv. infantis CCUG 52486, combined with a prebiotic, 
gluco-oligosaccharide (B. longum + Gl-OS), on the NK cell response to seasonal influ-
enza vaccination in young and older subjects in a double-blind, randomized controlled 
trial. There were significant effects of aging on NK  cell phenotype, the most notable 
of which were an increase in CD56dim cells, mainly reflected in the CD16+ subset, a 
decrease in CD56bright cells, mainly reflected in the CD16− subset, and greater expression 
of the immunosenescence marker, CD57, on NK cell subsets. However, these changes 
only partially translated to differences in NK  cell activity, observed as trends toward 
reduced NK cell activity in older subjects when analyzed on a per cell basis. Influenza 
vaccination increased the proportion of CD56bright cells and decreased the proportion of 
CD56dim cells, in young, but not older subjects. Although NK cell activity in response to 
vaccination was not significantly different between the young and older subjects, low 
post-vaccination NK cell activity was associated with poor seroconversion in only the 
older subjects. There was no influence of the synbiotic on NK cell phenotype or activ-
ity, either before or after influenza vaccination. In conclusion, aging is associated with 
marked alteration of the phenotype of the NK cell population and there was evidence 
of an impaired NK cell response to influenza vaccination in older subjects. The effects 
of aging on NK cell phenotype and activity could not be offset by B. longum + Gl-OS.
Clinical Trial registration: www.ClinicalTrials.gov, identifier NCT01066377.
Keywords: aging, influenza, prebiotic, probiotic, vaccination
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inTrODUCTiOn
Influenza vaccination offers an important prophylactic solu-
tion for preventing infection and associated complications, but 
immunosenescence significantly impairs vaccine efficacy (1). 
Potential adjuvants and dietary strategies to improve the immune 
response to influenza vaccines in older people are, therefore, of 
great interest. Emerging evidence suggests that the resident gut 
microbiota plays an influential role in shaping antiviral defenses 
and modulating the outcome of viral infections (2), and these 
forms the basis for the hypothesis that pre- and probiotics may 
modulate responses to infection or vaccination.
Natural killer (NK) cells and NKT  cells are an important 
component of the immune response to influenza infection and 
low NK activity may be related to higher infection risk (3). They 
are recruited to the respiratory tract 48  h after infection with 
influenza virus and interact with influenza virus hemagglutinin 
(HA) via receptors NKp44 and NKp46, leading to activation (4). 
Augmentation of NK  cell activity after exposure to influenza 
virus-infected cells has been reported in both animals (5, 6) 
and humans (7), and NK cell-depleted mice have lower produc-
tion of antibodies and inflammatory cytokines after mucosal 
immunization (8). Nevertheless, very little is known about the 
effect of influenza immunization on NK cell number or function, 
particularly in the context of aging, and it is not clear whether 
NK  cells respond similarly to influenza vaccination in young 
vs older subjects (9, 10). The balance of evidence suggests that 
while total NK  cell number increases during aging (11–14), 
there is a decline in NK  cell activity on a per cell basis (15), 
a gradual accumulation of long-lived CD56dim NK cells (16–18) 
and a decline in the CD56bright subset in older subjects, which may 
lead to impaired cytokine production and adaptive immunity 
(17, 19–22). Enhancement of NK  cell activity could, therefore, 
provide a means to improve the immune response to vaccination 
in older subjects.
Since aging is associated with reduced biodiversity and 
compromised stability of the gut microbiota (23), as well as 
immunosenescence, older individuals may derive benefit from 
intervention with pre- and/or probiotics. To date, studies 
examining the adjuvant effects of probiotics on the immune 
response to vaccination have focused exclusively on adaptive 
immunity, but this could be indirectly affected by NK  cells. 
In support of this concept, administration of the probiotic, 
Lactobacillus casei Shirota, and Lactobacillus rhamnosus, 
protected mice from intranasally administered influenza virus 
infection at least partly by enhancing NK  cell activation in 
the lung (24, 25). This paper examines the effects of a novel 
synbiotic on NK cell phenotype and activity before and after 
influenza vaccination in young and older subjects as secondary 
outcomes of the PRIMAGE (Probiotics, Immunity, and Aging) 
study (26).
MaTErialS anD METHODS
Ethics and Trial registration
The study protocol was reviewed and approved by the University 
of Reading Research Ethics Committee (project number: 
10/09) and the National Health Service (NHS) Research Ethics 
Committee for Wales (10/MRE09/5). The trial was registered 
with clinicaltrials.gov (Identifier: NCT01066377) and conduc-
ted according to the guidelines laid down in the Declaration of 
Helsinki.
Participants
Prior to the influenza season of 2010–2011, young (18–35 years) 
and older (60–85 years) healthy adults were recruited from the 
population in and around Reading (UK) through newspaper 
and poster advertisements, email, and radio. Inclusion criteria 
were: a signed consent form, age 18–35  years or 60–85  years, 
body mass index (BMI) 18.5–30 kg/m2, good general health, as 
determined by medical questionnaires and laboratory data from 
screening blood and urine sample (fasting glucose, erythrocyte 
sedimentation rate, full blood count, liver function tests, renal 
profile, dipstick urinalysis), not pregnant, lactating, or planning 
a pregnancy. Exclusion criteria included: allergy to the influenza 
vaccine, HIV infection, diabetes requiring any medication, 
asplenia, and other acquired or congenital immunodeficiencies, 
any autoimmune disease, including connective tissue diseases, 
malignancy, cirrhosis, current use of immunomodulating medi-
cation (including oral and inhaled steroids), self-reported symp-
toms of acute or recent infection (including use of antibiotics 
within past 3 months), taking lactulose or any other treatment 
for constipation, alcohol, and drug misuse. Additional exclusion 
criteria for older volunteers included: laboratory data which 
were outside the normal range for this age group AND outside 
the ranges specified in the SENIEUR protocol (27), Barthel 
Index score of <16/100, cumulative illness rating scale score of 
>15 (28). Additional exclusion criteria for the young subjects 
included laboratory data which were outside the normal range 
and influenza vaccination in the previous 12 months.
Sample Size
The primary outcome of the trial was the antibody response to 
vaccination, incorporating mean antibody titers, vaccine-specific 
Ig subclasses, and seroprotection and seroconversion, and sample 
size calculations are presented in detail in Ref. (26). A total of 
62 young subjects and 63 older subjects entered the study and 
58 young and 54 older subjects completed the study (26). Two 
subjects experienced adverse effects (gastrointestinal bloating) 
during the study, one on the placebo group and one in the 
Bifidobacterium longum + gluco-oligosaccharide (Gl-OS) group; 
both withdrew from the study.
Study Design
Subjects were randomized by covariate adaptive randomization 
(by a research nurse not involved in the study) according to 
gender, age, and BMI to receive B. longum bv. infantis CCUG 
52486 (B. longum, 109 CFU in 1 g skimmed milk powder/day) 
Abbreviations: BSA, bovine serum albumin; CIRS, cumulative illness rating scale; 
Gl-OS, gluco-oligosaccharide; Ig, immunoglobulin; PBMC, peripheral blood 
mononuclear cells; NK, natural killer; PBS, phosphate-buffered saline; RPMI, 
Roswell Park Memorial Institute.
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combined with [Gl-OS (BioEcolians, Solabia); 8  g/day] in a 
double-blind, placebo controlled parallel study designed for 
8 weeks. After 4 weeks, subjects were administered with a single 
dose of the influenza vaccine (Influvac®subunit 2010/2011 sea-
son, Abbott Biologicals B.V., lot number 1070166) containing 
A/California/7/2009 (H1N1), A/Perth/16/2009 (H3N2) and 
the B/Brisbane/60/2008-like strain by intramuscular injection in 
the deltoid, as described in Ref. (26).
Blood Sample Processing
For serum, blood was collected into serum separator tubes and 
left at room temperature for 30 min to allow coagulation. Samples 
were centrifuged at 1,300 × g for 10 min and aliquots of serum 
were collected and stored at −80°C prior to analysis.
nK Cell Phenotyping
Cryopreserved peripheral blood mononuclear cells (PBMCs) 
were thawed, washed, counted in a Z1 Coulter Counter, and 
adjusted to 5 × 106 cells/ml. Cryopreservation has been shown to 
have no effect on NK cell function (29). Viability was assessed by 
trypan blue dye exclusion (Sigma, UK) and was typically >85%. 
Cells were then resuspended in the appropriate medium for 
phenotyping or functional assays. NK cell phenotyping was per-
formed using the following fluorescent-conjugated monoclonal 
antibodies: CD3-PE-Cy7, CD56-PE, CD16-FITC, and CD57-
APC (BD Biosciences, UK). For determination of non-specific 
staining, cells were incubated with mouse IgG1 as an isotype 
negative control for PE-labeled antibodies (BD Biosciences, UK). 
PBMCs (1 ×  106) were incubated with the antibody combina-
tion for 20 min in the dark at room temperature before washing 
and fixing with 2% paraformaldehyde buffer and analysis on a 
flow cytometer (BD FACS Canto II, BD Bioscience), which was 
performed within 5 h.
The lymphocyte population was gated using forward scatter 
and side scatter and NK  cells were identified as CD3−CD56+ 
(Figure S1 in Supplementary Material). Based on the 
CD3−CD16+CD56+ phenotype, NK  cells were further divided 
into CD56bright and CD56dim subsets and the proportions of these 
cells were determined (Figure S2 in Supplementary Material). 
Expression of CD57+ by both the total NK cell population and 
specific NK cell subsets was also assessed.
Data was analyzed using FlowJo software©Tree star according 
to the gating strategy described in Figure S3 in Supplementary 
Material.
nK Cell activity
K562 myeloid leukemia cells (target cells for the NK cell acti vity 
assay) were enumerated by microscopy with trypan blue exclusion, 
adjusted to 5 × 106 cells/ml and washed twice with phosphate-
buffered saline (PBS) prior to incubation with carboxyfluorescein 
diacetate N-succinimidyl ester (CFDA-SE) for 45 min at 37°C in 
an air/CO2 (19:1) atmosphere. Following incubation, the K562 
cells were washed twice with PBS and resuspended in 1  ml of 
complete medium comprising RPMI 1640 with l-glutamine, 5% 
streptomycin, and 10% newborn calf serum.
For the assay, PBMCs were incubated with the CFDA-SE 
labeled K562 cells for 2 h at 37°C in an air/CO2 (19:1) atmosphere 
at effector to target cells ratios of 100:1, 50:1, 25:1, and 12.5:1. 
Samples were then transferred to 4°C and analyzed within 1 h. 
Propidium iodide (PI) (20  µl) was added to samples immedi-
ately prior to analysis on a flow cytometer (FACS Canto II, BD 
Bioscience with DIVAS software). Data for 1,200 viable target 
cells was collected and FSC/SSC gating was used to discriminate 
between leukocytes and K562 target cells. Single parameter 
histograms representing the FITC channel demonstrate staining 
of K562 cells by CFDA-SE and of K562 cells within samples with 
an E/T ratio of 100:1 (Figure S4 in Supplementary Material). 
Events recorded within the K562 cells gate were further analyzed 
according to fluorescence of the red DNA dye, PI (PE channel), 
and fluorescence of CFDA-SE (FITC channel) by gating with 
quadrant markers, which divide the plot into four sections and 
enables enumeration of dead and live target cells. NK cell activity 
was calculated as the difference between the total percentage of 
lysed target cells and the percentage of lysed K562 cells in the 
control sample (no PBMC).
analysis of anti-CMV igG antibodies
Concentrations of anti-CMV IgG antibodies were analyzed by 
ELISA according to the manufacturer’s instructions (ab108724 
Anti-Cytomegalovirus (CMV) IgG Human Elisa Kit, Abcam, 
UK) and read in a microplate reader (GENios) at 450 nm, with 
620 nm as a reference wavelength. CMV seropositivity, which 
is often associated with immunosenescence and poor response 
to vaccination (26), was defined as antibody levels >11 AU/ml 
in accordance with the manufacturer’s instructions.
Statistical analysis
Data were analyzed using SPSS software (version 21). The primary 
outcome for the trial was the antibody response to vaccination, 
which has been published (26). For the secondary endpoints 
of NK phenotype and activity presented in this paper, a linear 
mixed model (LMM) was implemented. A first order autoregres-
sive covariance structure was selected AR (1), with fixed factors 
of time (repeated measures), age, and treatment and subject as 
a random effect. Following this initial analysis, the data were 
split by cohort (young/older) and the analysis was repeated in 
the same manner to determine time and treatment effects within 
each cohort. The distribution of the data was checked using the 
Kolmogorov–Smirnov test. If data were not normally distributed, 
they were log transformed. Differences in baseline phenotype and 
NK activity between the young and older subjects were analyzed 
by independent samples t-tests. Relationships between NK 
activity and seroconversion were analyzed by the Fisher’s exact 
test. To account for multiple testing, two-sided P values of 0.01 
or less were considered statistically significant. All missing data 
were classed as missing at random and only available data were 
analyzed.
rESUlTS
Subject Characteristics
The characteristics of the subjects recruited to the study have 
been previously reported (26). Of the 125 volunteers who started 
TaBlE 1 | Age-related differences in the natural killer (NK) cell population at 
baseline.
% of immune cells Parent 
population
Young 
subjects
Older 
subjects
age P-
value
Lymphocytes Peripheral 
blood 
mononuclear 
cells
79.32 ± 0.87 71.76 ± 1.12 <0.001
CD56−CD16+ Lymphocyte 5.47 ± 0.52 8.62 ± 0.74 <0.01
CD3+CD56+ Lymphocyte 3.70 ± 0.63 4.05 ± 0.87 NS
CD3+CD56− Lymphocyte 67.3 ± 1.84 69.1 ± 1.24 NS
CD3−CD56+ CD3− 
lymphocyte
16.9 ± 1.26 24.3 ± 1.25 <0.001
CD56bright CD3−CD56+ 9.88 ± 1.02 6.86 ± 0.69 0.016
CD56brightCD16− CD3−CD56+ 8.69 ± 0.92 5.68 ± 0.57 <0.01
CD56brightCD16dim CD3−CD56+ 1.81 ± 0.22  ± 0.19 NS
CD56dim CD3−CD56+ 89.37 ± 1.06 92.61 ± 0.72 0.013
CD56dimCD16− CD3−CD56+ 28.79 ± 1.51 20.17 ± 1.36 <0.001
CD56dimCD16+ CD3−CD56+ 60.72 ± 2.04 72.51 ± 1.73 <0.001
CD3+CD57+ CD3+ 8.16 ± 0.62 11.57 ± 0.91 <0.01
CD3−CD56+CD57+ CD3−CD56+ 46.12 ± 1.91 50.56 ± 1.82 NS
CD3+CD56+CD57+ CD3+CD56+ 41.65 ± 2.74 54.08 ± 2.80 <0.01
CD56dimCD57− CD56dim 40.80 ± 1.33 35.93 ± 1.49 0.017
CD56dimCD57+ CD56dim 45.50 ± 1.80 52.57 ± 1.82 <0.01
CD56dimCD16+CD57+ CD56dimCD16+ 56.70 ± 1.84 60.44 ± 1.87 NS
CD56dimCD16−CD57+ CD56dimCD16− 18.02 ± 1.29 19.69 ± 1.58 NS
Data are mean ± SEM for n = 51 young subjects and n = 52 older subjects. 
Differences between the two cohorts were analyzed by independent samples t-tests 
(2-tailed).
Young Older
*
*
FiGUrE 1 | CMV seropositivity is associated with an increase in 
CD57+CD3+CD56+NKT cells. Data are % of CD57+CD3+CD56+ 
NKT cells ± SEM for n = 40 young and n = 41 older subjects, ▫CMV−, 
▪CMV+. Data were analyzed using independent samples t-test. *Denotes 
significant difference between CMV and CMV+ status in young (P < 0.001) 
and older subjects (P < 0.01).
4
Przemska-Kosicka et al. Ageing, Immunity and Probiotics
Frontiers in Immunology | www.frontiersin.org March 2018 | Volume 9 | Article 591
the trial, 112 completed (26). NK activity analysis was performed 
on samples from 51 young subjects and 52 older subjects. There 
were no differences in baseline characteristics, such as age, BMI, 
blood pressure, etc., between treatment groups within the young 
or older cohorts.
Effect of aging on the nK Cell repertoire
Baseline NK cell phenotypes were significantly different between 
the age groups (Table 1). Young subjects had significantly higher 
numbers of total lymphocytes than older subjects (P <  0.001). 
However, older subjects had significantly higher percentages 
of CD3−CD56+ and CD56−CD16+ cells than young subjects 
(P < 0.01 at least), while percentages of CD3+CD56+ cells did not 
differ significantly between young and older subjects.
CD56bright and CD56dim cells were expressed as percentages of 
the CD3−CD56+ NK cell pool. Older subjects tended to have a 
higher proportion of CD56dim NK cells (P = 0.013) and a lower 
proportion of CD56bright cells (P =  0.016) than young subjects. 
Further analysis of the CD56dim population demonstrated that 
there was a significantly higher percentage of CD56dimCD16+ 
NK cells (P < 0.001), and a lower percentage of CD56dimCD16− 
NK cells (P < 0.001) in older subjects compared to young subjects. 
Further analysis of the CD56bright population demonstrated that 
older subjects had a lower proportion of CD56brightCD16− cells 
than young subjects (P <  0.01). Overall, therefore, the higher 
proportion of CD56dim cells in older subjects was mainly reflected 
in the CD16+ subset, whereas the lower proportion of CD56bright 
cells was mainly reflected in the CD16− subset. There was no dif-
ference in the percentage of CD56brightCD16dim cells between the 
cohorts (Table 1).
nK Cell Populations and Markers  
of immunosenescence
Older subjects expressed higher levels of the aging marker, 
CD57 on the CD3+, CD3+CD56+, and the CD56dim populations 
(P  <  0.01 for both) compared to young subjects (Table  1). 
In contrast, CD57 expression on the CD3−CD56+, CD56dimCD16+, 
and CD56dimCD16− populations was not significantly different 
between the two cohorts.
Subjects who were seropositive for CMV had a significantly 
higher percentage of CD57+CD3+CD56+ NKT cells compared to 
subjects who were CMV−, regardless of age (P <  0.01 at least) 
(Figure 1).
Effect of aging on nK Cell activity
Baseline NK  cell activity was not different between young and 
older subjects at any of the E/T ratios (Figure 2). However, there 
were trends for higher baseline NK cell activity on a per cell basis 
(% NK activity expressed relative to % CD3−CD56+ NK cells) in 
the young subjects compared to the older subjects at E/T ratios of 
100:1, 50:1, 25:1 (Figure 3).
Effect of B. longum + Gl-OS on  
nK Cell Phenotype and activity
Supplementation with B. longum +  Gl-OS had no significant 
effect on NK  cell phenotype (Tables S1A,B in Supplementary 
Material) or activity (Table 2; Tables S2A,B in Supplementary 
Material) in young or older subjects, either before or after 
vaccination.
Effect of influenza Vaccination on  
nK Cell Phenotype and activity
Since there was no effect of the synbiotic on NK  cell pheno-
type, either before or after vaccination, treatment groups are 
00.5
1
1.5
2
2.5
100:1 50:1 25:1 12.5:1
sisabllec
rep
a
no
ytivitca
k
N
Effector:target cell ratio
Young Older
FiGUrE 3 | Baseline natural killer cell activity on a per cell basis. Data are 
mean ± SEM at week 0, for n = 54 subjects per group. Data were analyzed 
using independent samples t-test (2-tailed). P = 0.02 for E/T ratio 100:1, 
P = 0.03 for 50:1, P = 0.038 for 25:1, and P = 0.116 for 12.5:1.
0
5
10
15
20
25
30
100:1 50:1 25:1 12.5:1
)sisyl 
%( ytivitca 
K
N latoT
Effector:target cell ratio
Young Older
FiGUrE 2 | Baseline natural killer cell activity. Data are mean ± SEM at week 
0, for n = 54 subjects per group. Data were analyzed using independent 
samples t-test (2-tailed). P = 0.11 for E/T ratio 100:1, P = 0.54 for 50:1, 
P = 0.03 for 25:1, and P = 0.08 for 12.5:1.
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presented combined to allow evaluation of the effects of aging 
and vaccination. Vaccination significantly decreased the 
proportion of CD3−CD56+ and CD3−CD56+CD57+ NK  cells 
(relative to CD3− lymphocytes) following vaccination in older 
subjects, but not young subjects (LMM, older cohort only, effect 
of time P < 0.01) (Table 3). In contrast, in the young subjects, 
vaccination resulted in an increase in CD56bright cells and a 
decrease in CD56dim cells (LMM, young cohort only, effect of 
time P < 0.01) (Table 3). Within the CD56bright population, there 
was an increase in the percentage of CD56brightCD16dim NK cells 
in young subjects following vaccination (LMM, effect of time 
P < 0.01) (Table 3).
Post-Vaccination nK Cell activity is 
associated With Greater Seroconversion 
to the Brisbane Subunit of the influenza 
Vaccine
Subjects were classified as exhibiting “low” or “high” NK  cell 
activity by using the median as a cut-off (24% lysis for young sub-
jects and 29% for older subjects). For older subjects, there were 
no seroconverters to the Brisbane strain and to all three strains 
of the influenza vaccine in the low NK activity group, whereas 
in the high NK activity group, 27% of subjects seroconverted to 
the Brisbane strain (Fisher’s exact test, P = 0.01) and all strains 
of the vaccine (Fisher’s exact test, P = 0.01), suggesting that high 
post-vaccination total NK activity was associated with a greater 
rate of seroconversion. This relationship was not observed in the 
young subjects. There were no associations between NK activity 
and antibody response to H1N1 or H3N2 subunits of the vaccine 
in either of the cohorts.
DiSCUSSiOn
This study highlights phenotypic changes in the NK  cell 
population during aging, the most prominent of which were an 
increase in CD56dim cells, mainly reflected in the CD16+ subset, 
a decrease in CD56bright cells, mainly reflected in the CD16− sub-
set, and greater expression of the immunosenescence marker, 
CD57, on some NK cell subsets. It also demonstrates that CMV 
positivity, often suggestive of repeated antigenic exposure, was 
associated with an increase in an immunosenescent population 
of NKT cells. We previously reported that higher plasma levels of 
anti-CMV IgG in the older subjects were associated with higher 
numbers of senescent (CD28−CD57+) helper T cells and a failure 
of these subjects to seroconvert to the Brisbane subunit of the 
vaccine (26). We also reported that antigen-specific B and T cell 
activation following an in vitro recall challenge with the influenza 
vaccine was influenced by CMV seropositivity (30). The changes 
in NK  cell phenotype only partially translated to differences 
in NK cell activity, observed as trends toward reduced NK cell 
activity in older subjects when analyzed on a per cell basis. The 
effects of influenza vaccination on NK cell phenotype and activity 
were modest and less evident in the older subjects than the young 
subjects. Furthermore, higher post-vaccination NK activity was 
associated with better seroconversion in the older subjects. There 
was no effect of the synbiotic on NK cell phenotype or activity, 
either before or after influenza vaccination.
While there is general consensus that aging impairs the 
response to influenza vaccination (31), there are very few robust 
studies specifically comparing responses of young and older 
subjects, and the most comprehensive information available 
is from a meta-analysis published in 2006, which concluded 
that clinical vaccine efficacy in older subjects was only 17–53% 
compared to 70–90% in young subjects (32). In this study, 
antibody responses to all three subunits of the influenza vaccine 
were impaired in the older subjects and there was significantly 
reduced seroprotection to the H1N1 and Brisbane subunits and 
seroconversion to the H3N2 and Brisbane subunits after vac-
cination; these data are reported elsewhere (26). The expansion 
TaBlE 3 | Changes in natural killer cell phenotype following influenza vaccination 
in young and older subjects.
Effect of vaccination
% of immune cells Parent 
population
Both 
cohorts 
(P-value)
Young 
cohort 
(P-value)
Older 
cohort 
(P-value)
Lymphocytes Peripheral blood 
mononuclear cells
NS NS NS
CD3−CD56+ Lymphocyte ↓P = 0.017 NS ↓P < 0.01
CD56−CD16+ Lymphocyte NS NS NS
CD3+CD56+ Lymphocyte NS NS NS
CD3+ Lymphocyte NS NS NS
CD3+CD57+ CD3+ NS NS NS
CD56bright CD3−CD56+ ↑P < 0.01 ↑P < 0.01 NS
CD56brightCD16− CD3−CD56+ NS NS NS
CD56brightCD16dim CD3−CD56+ ↑P = 0.015 ↑P < 0.01 NS
CD56dim CD3−CD56+ ↓P < 0.01 ↓P < 0.01 NS
CD56dimCD16− CD3−CD56+ NS NS NS
CD56dimCD16+ CD3−CD56+ NS NS NS
CD3−CD56+CD57+ CD3−CD56+ ↓P = 0.029 NS ↓P < 0.01
CD3+CD56+CD57+ CD3+CD56+ NS NS NS
CD56dimCD57− CD56dim NS NS NS
CD56dimCD57+ CD56dim NS NS NS
CD56dimCD16+CD57+ CD56dimCD16+ NS NS NS
CD56dimCD16−CD57+ CD56dimCD16− NS NS NS
Data were analyzed using a linear mixed model with fixed factors of time, age, and 
treatment. In further analysis, data were split by cohorts, which were analyzed 
separately.
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of the mature CD56dim NK  cell population and decline of the 
immature CD56bright NK  cell population could contribute to 
diminished adaptive immune responses to vaccination in older 
subjects, since CD56bright NK cells drive DC maturation and T cell 
differentiation (33). Expansion of the CD56−CD16+ NK  cell 
population in older subjects, also observed in this study, has been 
associated with low cytotoxic capacity, low cytokine production, 
and exposure to chronic viral infections (34). Expression of 
CD57, a marker for terminally differentiated cells, was increased 
with the CD3−CD56+ NK cell population of older subjects, and 
this effect of aging is consistent with some (17, 20, 34), but not 
all, previous reports (18). Thus, there are a number of potentially 
important aspects to remodeling of the NK  cell population 
during the life course, which could diminish the response to 
vaccination. However, there is less clarity about the impact of 
aging on NK cell activity.
The alterations in NK  cell phenotype due to aging only 
partially resulted in impairment of NK  cell activity in the 
older subjects; this was evidenced by a trend toward decreased 
NK activity on a per cell basis in the older subjects, but total 
NK activity was not reduced. Overall, therefore, NK cell activ-
ity appears to be relatively well preserved during aging, despite 
potentially unfavorable changes in NK phenotype. CD56+CD57+ 
cells, which characteristically have high cytolytic capacity, but 
diminished proliferation, were evident in the older subjects and 
may contribute to the preservation of NK cell activity in old age. 
NK  cell activity normally remains elevated for up to 30  days 
following influenza vaccination (9). One study in older subjects 
reported no effect of vaccination on NK cell activity for 4–6 weeks 
of post-vaccination (10), but it is not clear whether this was due 
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to a return to baseline NK activity at these later time points or 
because NK cells failed to respond to vaccination in older sub-
jects. Thus, a direct comparison of NK cell activity in young and 
older subjects in response to influenza vaccination is timely and 
important.
This study is the first to demonstrate that older subjects 
with high NK activity post-vaccination tended to seroconvert 
better to the Brisbane strain and all influenza strains together 
compared to subjects with low NK activity; these effects were 
borderline significant. While this cannot be taken to imply cau-
sality, it builds on evidence suggesting an association between 
high NK activity and antibody response to influenza vaccination 
in both young (35) and elderly subjects (9). To our knowledge, 
this study is the first to directly and comprehensively compare 
NK  cell phenotype and activity in response to influenza vac-
cination in young and older subjects. To date, only three human 
studies have investigated NK  cell numbers in response to 
influenza vaccine and reported either no change in elderly (10) 
or young individuals (4), or an initial decrease in numbers of 
CD3−CD56+ cells in adults, with a subsequent increase 4 days 
after seasonal and pandemic H1N1 influenza vaccine (36). 
However, these studies were small, did not directly compare 
responses in young and older subjects and employed different 
blood sampling times. In this study, the decrease in NK  cells 
in older subjects 14  days after vaccination was profound, but 
there was some recovery at 28  days (data not shown). This is 
consistent with a report demonstrating an initial decline in the 
number of NK cells during 2 weeks following H1N1 influenza 
vaccination, with later recovery (37). This study is also the first 
to demonstrate that influenza vaccination was associated with 
an increase in the percentage of CD56bright cells in young sub-
jects, including CD56brightCD16− and CD56brightCD16dim subsets, 
whereas the percentage of CD56dim cells was reduced 2 weeks 
after vaccination. This increased proportion of CD56bright cells in 
young adults could be related to peripheral expansion, increased 
production from NK precursors in the bone marrow, or redis-
tribution from the tissues after vaccination (16), and could 
contribute to DC maturation and stimulation of T cells. Further 
work in larger studies to allow disaggregation by gender and 
race could be of value; there was insufficient power to produce 
meaningful data in this study.
Enhanced NK  cell activity as a result of treatment with 
probiotics is commonly reported, both in vitro (38, 39), and in 
human studies (40, 41) and it is suggested that this effect might 
be strain-specific. This study tested the hypothesis that the 
probiotic B. longum bv. infantis CCUG 52486 combined with 
prebiotic, Gl-OS, would improve NK  cell activity in an age-
dependent manner, as a secondary outcome of the PRIMAGE 
study [the primary outcome being antibody production (26)]. 
The strain B. longum bv. infantis CCUG 52486 was selected 
because it was originally isolated from a cohort of very healthy 
elderly subjects (independent lifestyle, free of chronic disease, 
and aged 90 years or over) in Italy as part of the CROWNALIFE 
EU FP5 project (42), it has been demonstrated to have par-
ticular ecological fitness and anti-pathogenic effects in  vitro 
(43), and it has immunomodulatory effects which are strongly 
influenced by the age of the host (39). However, there were no 
effects of the synbiotic on NK cell phenotype or activity, either 
prior to or after vaccination. Close scrutiny of the literature 
reveals that while some studies demonstrate enhancement in 
both the proportion of NK cells (CD16+CD56+) and NK activ-
ity by probiotics (44), some demonstrate only enhancement in 
the proportion of NK  cells (45, 46), and others demonstrate 
no effect at all (47–49). Supplementation with L. paracasei 
NCC 2461, prebiotic fructo-oligosaccharides, and a range of 
vitamins and nutrients for 4 months enhanced pre-vaccination 
NK cell activity and NK cell numbers and reduced the number 
of infections in elderly Chilean subjects (50). In contrast, De 
Vrese et  al. (51) reported reduced duration of cold episodes, 
but no effect on NK cell numbers in healthy adults following 
intervention with a mixed supplement, including L. gasseri PA 
16/8, B. longum SP 07/3, B. bifidum MF 20/5, vitamins, and 
minerals for 3 months (52). Thus, it is not clear whether the 
impact of pre- and probiotics on infection and illness relates to 
changes in NK cell number or activity. The effects of probiot-
ics on response to influenza vaccination in older adults are of 
particular importance, given the consequences of respiratory 
infections in older people (53); however, it is possible that not 
only there are differences in the immunomodulatory poten-
tial of different strains, but also there is differential immune 
response to probiotics in young vs older subjects. You et al. (39) 
demonstrated that PBMC from older subjects (60–85  years) 
were more responsive to the immunoregulatory effects (IL-10 
induction) of two strains of bifidobacteria than young subjects 
(18–30 years), whereas PBMC from young subjects were more 
responsive to the immunostimulatory effects (IL-12 induction) 
of two strains of lactobacilli. Further studies demonstrated 
that probiotics (including the strain employed in this study) 
increased the responsiveness of DCs in older subjects to a 
greater degree than young subjects, but this was not sufficient 
to overcome the impact of immunosenescence in a mixed 
leukocyte reaction (54).
The results of an intervention should, if possible, take 
into account the potential influence of baseline differences, 
for example in immunosenescence and pre-vaccination anti-
body titers. Here, there are some limitations; we previously 
reported that the older subjects randomized to the synbiotic 
had, by chance, a significantly higher number of senescent 
(CD28−CD57+) helper T  cells and higher plasma levels of 
anti-CMV IgG at baseline compared to those randomized to 
the placebo, placing them at a significant disadvantage before 
vaccination and potentially influencing the outcome of the trial 
(26). Attempts to take into account pre-existing immunity to 
influenza is challenging. There was virtually no seroprotection 
to the H1N1, H3N2, or Brisbane subunits exhibited by the sub-
jects prior to vaccination, with the exception of a small number 
of young subjects who appeared to have been exposed to the 
H1N1 subunit, but did not report infection (26). There was 
also no significant difference in pre-vaccination antibody titers 
to the H1N1, H3N2, or Brisbane strains between young and 
older subjects (26). We did not assess subjects for pre-existing 
immunity to other influenza strains, including those that had 
been employed in influenza vaccination in previous years for 
logistical reasons. However, prior exposure may well have 
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influenced the outcome of vaccination, since cross-reactivity 
between influenza viruses is well documented (55) and pre-
existing immunity to flavivirus has been demonstrated to 
influence the response to yellow fever vaccination (56). Future 
work characterizing in detail the influence of both pre-existing 
immunosenescence and pre-existing immunity on vaccination 
outcome is warranted.
In conclusion, this study describes marked alteration of the 
NK  cell population by aging, although NK  cell activity was 
preserved to some degree in older subjects. Although there was 
evidence of an impaired NK cell response to influenza vaccina-
tion in older subjects, this was not offset by B. longum + Gl-OS. 
Further work to examine the influence of pre-existing immunity 
on outcomes of vaccination trials would be of value.
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